No Data
BofA Securities Maintains Integra Lifesciences(IART.US) With Sell Rating, Maintains Target Price $21
Integra Lifesciences Faces Supply Chain Challenges and Conservative Outlook, Leading to Sell Rating
JMP Securities Maintains Integra Lifesciences(IART.US) With Buy Rating, Maintains Target Price $35
Optimistic Growth Outlook for Integra LifeSciences Amidst Transitional Phase and Strategic Initiatives
Integra Lifesciences | 10-K: FY2024 Annual Report
Integra LifeSciences Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Adjusted EPS Results.
Money Mover OP : $Medtronic (MDT.US)$ $Intuitive Surgical (ISRG.US)$